FREDERICK, Md., Nov. 14 /PRNewswire-FirstCall/ -- BioElectronics Corporation, , announced today that the Jordan Food & Drug Administration has cleared ActiPatch for sale. The Company has initiated shipments for both the retail and the medical professional markets into the Kingdom.
"We are proud to announce another step for our Company in introducing the pain relief and healing benefits of ActiPatch to the international market. We are working closely with Distinction Corporation and excited to include them in our growing list of distributors. I have every confidence that this new relationship will bring not only success to our two companies in the Kingdom of Jordan, but also additional expansion into other Middles East markets," said Andrew Whelan, President of BioElectronics Corporation.
Farid Tamini, President of Distinction Corporation, said, "With the approval process behind us, we will quickly launch this wonderful product in the Kingdom of Jordan. We are pleased to be working with BioElectronics. There is an air of enthusiasm for this unique drug free therapy that will surely multiply as the medical professionals and patients experience the benefits of ActiPatch."
About BioElectronics:
BioElectronics Corporation is the maker of ActiPatch. ActiPatch is a drug-free anti-inflammatory patch with an embedded battery operated microchip that delivers weeks of continuous pulsed therapy for less than a dollar a day. The unique ActiPatch delivery system, using patented technology, provides a cost-effective, patient friendly method to reduce soft tissue pain and swelling.
For more information visit http://www.bioelectronicscorp.com
Safe Harbor Statement:
This news release contains forward-looking statements related to future growth and earnings opportunities. Such statements are based upon certain assumptions and assessments made by management of both companies in light of current conditions, expected future developments and other factors it believes to be appropriate. Actual results may differ as a result of factors over which the companies have no control.
CONTACT: Andrew J. Whelan, President & CEO of BioElectronics Corporation,
1-866-757-2284, Fax: +1-301-874-6935, info@actipatch.net
Web site: http://www.bioelectronicscorp.com/
